All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
Introducing
Now you can personalise
your PsOPsA Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Given the safety and tolerability profiles of currently available biologics and small-molecule oral agents for plaque psoriasis, there is a need for novel, better-tolerated therapies. Deucravacitinib is an oral, selective tyrosine kinase 2 (TYK2) inhibitor that binds to the regulatory or pseudokinase domain of TYK2 and allosterically inhibits the enzyme from initiating cytokine synthesis and plaque psoriasis pathogenesis.
Here, we summarize the results of POETYK-PSO-2, a phase III, randomized, double-blind study assessing the efficacy and safety of deucravacitinib against apremilast and placebo for the treatment of moderate-to-severe plaque psoriasis (NCT03611751),1 published in the Journal of the American Academy of Dermatology by Strober et al.
Figure 1. Efficacy measures at the end of Week 16*
BID, twice daily; PASI, Psoriasis Area and Severity Index; QD, once daily; sPGA, static Physician’s Global Assessment.
*Data from Strober, et al.
Key learnings |
Deucravacitinib demonstrated clinically significant efficacy over placebo and apremilast in adults with moderate-to-severe plaque psoriasis over 52 weeks. |
Deucravacitinib was generally well tolerated, with a safety profile consistent with the mechanism of selective TYK2 inhibition, showing low rates of serious AEs. |
This trial suggests that deucravacitinib may be a viable oral, once-daily treatment option for patients with plaque psoriasis, although longer-term data are needed. |
Your opinion matters
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox